Akane Minagawa Selected Research

Cysteinyldopa

1/2020	Significance of 5-S-Cysteinyldopa as a Marker for Melanoma.
11/2018	Serum 5-S-cysteinyldopa behavior in the early phase of nivolumab treatment of 12 melanoma patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Akane Minagawa Research Topics

Disease

5	Melanoma (Melanoma, Malignant) 02/2021 - 11/2018
2	Psoriasis (Pustulosis Palmaris et Plantaris) 09/2021 - 03/2018
2	Neoplasms (Cancer) 02/2020 - 03/2016
2	Neoplasm Metastasis (Metastasis) 01/2020 - 11/2018
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2022
1	Soft Tissue Infections 01/2022
1	Rheumatoid Vasculitis 12/2021
1	Leg Ulcer 12/2021
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 09/2021
1	Inflammation (Inflammations) 03/2018
1	Poroma 03/2016
1	Basal Cell Carcinoma (Rodent Ulcer) 03/2016
1	Keratosis 03/2016
1	Seborrheic Dermatitis 03/2016
1	Pyogenic Granuloma 03/2016
1	Amelanotic Melanoma (Amelanotic Melanomas) 03/2016
1	Eccrine Porocarcinoma 03/2016
1	Breast Neoplasms (Breast Cancer) 12/2015

Drug/Important Bio-Agent (IBA)

2	Melanins (Melanin)IBA 02/2021 - 01/2021
2	CysteinyldopaIBA 01/2020 - 11/2018
2	Biomarkers (Surrogate Marker)IBA 01/2020 - 11/2018
1	Dasatinib (BMS 354825)FDA Link 01/2022
1	Tyrosine Kinase InhibitorsIBA 01/2022
1	Certolizumab Pegol FDA Link 12/2021
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 09/2021
1	Immune Checkpoint InhibitorsIBA 02/2020
1	NivolumabIBA 11/2018
1	Antimicrobial PeptidesIBA 03/2018
1	CathelicidinsIBA 03/2018
1	erucylphosphocholineIBA 03/2016
1	Paclitaxel (Taxol)FDA LinkGeneric 12/2015

Therapy/Procedure

2	Therapeutics 11/2018 - 03/2018
1	Operative Surgical Procedures 02/2020